Skip to main content
Premium Trial:

Request an Annual Quote

Bar Harbor Biotech Closes 'Multi-Million-Dollar' VC Round; Plans Oct. 1 Product Launch

NEW YORK (GenomeWeb News) — Bar Harbor Biotechnology has closed a “multi-million dollar” round of Series A financing and plans to use the cash to market its first product, the company said Tuesday.
 
Bar Harbor Biotechnology, based in Trenton, Maine, is developing a suite of gene-expression products that includes bioanalysis software, qPCR arrays, and bioinformatics applications for gene-expression experiments.
  
Bar Harbor, which spun off from the Jackson Laboratory in 2006, said it plans to launch its first commercial product on Oct. 1. It was not immediately clear what that product will be.
 
Leading the investment round was Borealis Ventures, a seed capital company based in Hanover, NH, that focuses on New England startups. Village Ventures, an early-stage investment specialist based in Williamstown, Mass., contributed to the round.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.